Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-term follow-up of patients taking tenofovir DF with low-level HIV-1 viremia and the K65R substitution in HIV-1 RT.

AIDS (London, England) - 30 Mar 2007

Chappell Brandi J, Margot Nicolas A, Miller Michael D

Abstract excerpt

Patients with on-going HIV-1 replication and a K65R mutation in HIV-1 RT were assessed for further development of RT mutations while taking tenofovir disoproxil fumarate and other antiretroviral drugs. K65R was observed in 10 out of 536 treatment-experienced patients entering the study. K65R beca...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Anti-HIV Agents
Share to Anti-Retroviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Long-Term Care

Share to Organophosphonates

Share to Reverse Transcriptase Inhibitors

Share to RNA-Directed DNA Polymerase

Share to Tenofovir

Source

Identifiers

PMID: 17413698
DOI: 10.1097/QAD.0b013e3280187533

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17413698-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term follow-up of patients taking tenofovir DF with low-level HIV-1 viremia and the K65R substitution in HIV-1 RT.PMID 17413698Read ↗

Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.Semantic proximity Read ↗

K65R, TAMs and tenofovir.Semantic proximity Read ↗

K65R-associated virologic failure in HIV-infected patients receiving tenofovir-containing triple nucleoside/nucleotide reverse transcriptase inhibitor regimens.Semantic proximity Read ↗

Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir.Semantic proximity Read ↗

Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine.Semantic proximity Read ↗

The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.Semantic proximity Read ↗

Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels.Semantic proximity Read ↗

Low prevalence of transmitted K65R and other tenofovir resistance mutations across different HIV-1 subtypes: implications for pre-exposure prophylaxis.Semantic proximity Read ↗

Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate.Semantic proximity Read ↗

Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.Semantic proximity Read ↗

Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdASemantic proximity Read ↗

A rare HIV reverse transcriptase mutation, K65N, confers reduced susceptibility to tenofovir, lamivudine and didanosine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.